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Abstract
Background: Vascular endothelial growth factor (VEGF), a substance that stimulates new blood vessel formation, is an
important survival factor for endothelial cells. Although overexpressed VEGF in the lung induces pulmonary edema with
increased lung vascular permeability, the role of VEGF in the development of acute lung injury remains to be determined.
Methods: To evaluate the role of VEGF in the pathogenesis of acute lung injury, we first evaluated the effects of
exogenous VEGF and VEGF blockade using monoclonal antibody on LPS-induced lung injury in mice. Using the lung
specimens, we performed TUNEL staining to detect apoptotic cells and immunostaining to evaluate the expression of
apoptosis-associated molecules, including caspase-3, Bax, apoptosis inducing factor (AIF), and cytochrome C. As a
parameter of endothelial permeability, we measured the albumin transferred across human pulmonary artery endothelial
cell (HPAEC) monolayers cultured on porous filters with various concentrations of VEGF. The effect of VEGF on
apoptosis HPAECs was also examined by TUNEL staining and active caspase-3 immunoassay.
Results: Exogenous VEGF significantly decreased LPS-induced extravascular albumin leakage and edema formation.
Treatment with anti-VEGF antibody significantly enhanced lung edema formation and neutrophil emigration after
intratracheal LPS administration, whereas extravascular albumin leakage was not significantly changed by VEGF blockade.
In lung pathology, pretreatment with VEGF significantly decreased the numbers of TUNEL positive cells and those with
positive immunostaining of the pro-apoptotic molecules examined. VEGF attenuated the increases in the permeability of
the HPAEC monolayer and the apoptosis of HPAECs induced by TNF-α and LPS. In addition, VEGF significantly reduced
the levels of TNF-α- and LPS-induced active caspase-3 in HPAEC lysates.
Conclusion: These results suggest that VEGF suppresses the apoptosis induced by inflammatory stimuli and functions
as a protective factor against acute lung injury.
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Background
Vascular endothelial growth factor (VEGF) was originally
discovered as a vascular permeability factor in guinea pig
skin, and is a mitogen that regulates endothelial cell dif-
ferentiation, angiogenesis, and the maintenance of exist-
ing vessels [1-4]. VEGF is involved in the pathogenesis of
rheumatoid arthritis, diabetic retinopathy, and tumor
growth, and may contribute to endothelial cell migration
and proliferation [5,6]. VEGF is expressed primarily on
alveolar epithelial cells and activated alveolar macro-
phages [7-9]. In healthy human subjects, VEGF protein
levels in oxygenated alveoli are 500 times higher than in
plasma, despite the lack of occurrence of angiogenesis,
edema or excess microvascular permeability [10]. These
data suggest an important persistent or additional func-
tion of VEGF within the human lung that has not yet been
characterized.
Acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS), involve a disrup-
tion of the alveolar-capillary membranes, with local
inflammation ultimately leading to alveolar flooding with
serum proteins and edema fluid [11,12]. Since ALI/ARDS
is characterized by permeability edema, it has been
hypothesized that VEGF may contribute to the develop-
ment of ALI/ARDS. Indeed, the overexpression of VEGF by
adenovirus in the lung leads to pulmonary edema and
increased lung vascular permeability [13]. To date, how-
ever, most observational studies of lung injury in humans
have shown a reduction in intrapulmonary VEGF levels in
ALI/ARDS, especially in its early stages [14-16]. In a recent
study using bronchoscopic microsampling method, we
observed greater VEGF levels in epithelial lining fluid
(ELF) in the ALI/ARDS patients who survived than in
those who did not [17]. In addition, VEGF concentration
in ELF was inversely correlated with lung injury score [17].
These findings suggest that the higher VEGF levels in the
airspace may be associated with a better outcome for
patients with ALI/ARDS.
Apoptosis of endothelial and epithelial cells, which is
induced by a variety of stimuli, contributes to the impair-
ment of the barrier function of pulmonary endothelium
and epithelium and development of pulmonary edema
[18]. There have been several reports describing the anti-
apoptotic effect of VEGF on endothelial cells [19-21]. We
hypothesized that the role of VEGF may be modified in
injured lung. To the best of our knowledge, there has been
no report examining both endothelial permeability and
apoptosis in a single model of lung injury.
To evaluate the role of VEGF in the apoptosis of endothe-
lial cells and their barrier function in the injured lung, we
evaluated the effects of exogenous VEGF and VEGF block-
ade by monoclonal antibody using a murine model of
LPS-induced lung injury. Using the lung specimens,
TUNEL staining and immunostaining of caspase-3, Bax,
apoptosis inducing factor (AIF) and cytochrome C were
performed to detect apoptotic cells and the pro-apoptotic
molecules expressed. We also determined the in vitro
effects of VEGF on endothelial permeability, apoptosis,
and caspase-3 activation using cultured human pulmo-
nary artery endothelial cells (HPAEC). To investigate the
mechanism underlying this attenuation of endothelial
damage, we evaluated the effect of VEGF on apoptosis and
the level of active caspase-3, a distal enzyme in the caspase
cascade, in endothelial cells.
Methods
Reagents
Purified recombinant human TNF-α and recombinant
human VEGF165 were purchased from Pepro Tech, Inc
(Rocky Hill, NJ). LPS and bovine serum albumin were
obtained from Sigma Chemical Co. (St. Louis, MO). The
Bio-Rad Protein Assay kit was obtained from Bio-Rad
(Richmond, CA). Recombinant mouse VEGF (rmVEGF)
and anti-mouse VEGF antibody (anti-VEGF Ab) was
obtained from R&D systems.
Murine model of acute lung injury
The experimental protocol was approved by the Keio Uni-
versity Council on Animal Care in accordance with the
guidelines of the National Institute of Health. The effect of
exogenous VEGF and anti-VEGF antibody was examined
in a murine LPS-induced lung injury model as previously
described [22]. The experimental protocol was approved
by the Keio University Council on Animal Care in accord-
ance with the guidelines of the National Institute of
Health. To determine the effect of VEGF on LPS-induced
acute lung injury, five groups of C57BL/6 mice (8 weeks
old, CLEA Japan, Tokyo, Japan) were studied (n = 6 each).
Control group was given an intravenous injection of 100
µl saline 24 and 1 h before intratracheal instillation of PBS
(50 µl); LPS group received 100 µl saline intravenously 24
and 1 h before LPS (10 µg/body in 50 µl PBS) challenge;
LPS+anti-VEGF group received anti-VEGF antibody (25
µg/body in 100 µl PBS) intravenously 10 min before and
2 h after LPS challenge; LPS+VEGF (pre) was given intra-
venous injection of rmVEGF (1 µg/body in 100 µl PBS) 24
and 1 h before LPS challenge; LPS+VEGF (post) was given
intravenous injection of rmVEGF (1 µg/body in 100 µl
PBS) 10 min and 2 h after LPS challenge.
Mice were anesthetized using ketamine hydrochloride
(80–100 mg/kg i.m.) and acepromazine maleate (5–10
mg/kg i.m.). Anesthetized mice received an intravenous
injection of 125I-labeled human albumin (0.1 mCi/
mouse) 15 min before intratracheal administration of
either PBS or LPS. Two minutes before the end of the
study, 131I-albuimn (0.1 mCi/mouse) was injected to esti-Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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mate the intravascular blood volume. The separation rate
of the labeled albumin was less than 1%. After 6 h, the
lungs were excised by opening the chest, and free blood
was removed by blotting the hilus on paper towels.
The gamma counts of tissue samples for 125I and 131I were
determined in a gamma well counter with appropriate
corrections for cross over. The tissues were then dried in a
vacuum drying oven at 90°C and -200 mmHg for 48 h.
The weights of the dried lung tissue samples were deter-
mined. Blood contamination in each sample was esti-
mated from 131I counts of the tissue sample, and
extravascular lung water was determined by calculating
the lung tissue wet-to-dry weight (W/D) ratio after correct-
ing the contamination [23]. Transvascular flux of 125I-
albumin was assessed by control ratio of lung tissue to
plasma per unit weight, which was used to estimate vascu-
lar endothelial damage (125I-albumin lung tissue-plasma
ratio: lung T/P ratio).
For lung pathology, the lungs were removed and fixed by
intratracheal instillation of 6% glutaraldehyde at 22
cmH2O. Paraffin-embedded 5-µm sections of lungs were
cut and stained with hematoxylin and eosin. To evaluate
lung tissue edema, Interstitial area/Total lung area ratio (I/
T ratio) was calculated from the cross-sectional areas of
lung interstitium and total lung using Micro Analyzer soft-
ware (Japan Poladigital, Tokyo, Japan). Slides from each
animal were observed under microscope and photo-
graphed in 30 randomly selected fields at ×200. The mean
I/T ratio of each animal was employed and compared
between the experimental groups. In addition, neutrophil
emigration was evaluated by counting the number of neu-
trophils in 200 randomly selected alveoli and was
expressed as the number of neutrophils per 100 alveoli.
The microscopic observations were conducted by single
investigator in a blinded fashion.
TUNEL staining of the lung section
TUNEL staining was performed with MEBSTAIN II Apop-
tosis kit (Medical&Biological Laboratories, Nagoya,
Japan), following the manufacturer's instructions. After
deparaffinization and rehydration, sections were digested
with proteinase K for 30 min. After washing with DW, the
slides were immersed in buffer. TdT, 1 mM Mn2+, and
biotinylated dUTP in TdT buffer were then added to cover
the sections and incubated at 37°C for 60 min. After
washing with DW, endogenous peroxidase activity was
quenched with 0.3% H2O2 for 5 min. The slides were
washed with PBS, covered with PBA for 10 min. After rins-
ing with PBS, the slides were covered with extra-avidin
peroxidase (Dako Japan, Kyoto, Japan) and immersed in
DAB solution. The slides were counterstained for 20 sec
with Mayer-hematoxylin, dehydrated, and mounted.
Immunohistochemistry of the lung section
Anti-human caspase-3 rabbit polyclonal antibody (Novo-
castra Laboratories, Newcastle, UK), anti-human Bax rab-
bit polyclonal antibody (Oncogene, San Diego, CA), anti-
human AIF rabbit polyclonal antibody (Biocarta,
Carlsbad, CA) and mouse anti-cytochrome C monoclonal
antibody (Chemicon International, Temecula, CA) were
used. These anti-human antibodies cross-react with
mouse antigen.
Lung tissues were fixed in buffered formalin, embedded in
paraffin and sectioned (5 µm) for immunohistochemical
assays. The sections were treated with 0.3% H2O2 in meth-
anol for 5 min. The slides were washed with PBS and
blocked with 1% PBA for 5 min. Anti-human caspase-3
rabbit polyclonal antibody (1:750 dilution), anti-human
Bax rabbit polyclonal antibody (1:100 dilution), anti-
human AIF rabbit polyclonal antibody (1:1500 dilution)
and mouse anti-cytochrome C monoclonal antibody
(1:400 dilution) were incubated with the slides at 4°C for
overnight, followed by biotinylated pig anti-Rabbit IgG
(1:300 dilution, Dako) or biotinylated secondary anti-
body (1:400 dilution) and extra-avidin peroxidase for 10
min each. After rinsing with PBS, the slides were
immersed in DAB solution for 5 min. The slides were
counterstained for 20 sec with Mayer-hematoxylin, dehy-
drated, and mounted. The slides were evaluated in a
blinded fashion.
Preparation of the endothelial monolayer
Human pulmonary artery endothelial cells (HPAEC) were
purchased from KURABO (Osaka, Japan) at 3rd passage.
In a humidified 5%CO2 atmosphere, the endothelial cells
were maintained with a culture medium (Humedia-EB2)
supplemented with 2% fetal bovine serum, 10 ng/ml
recombinant human EGF, 1 µg/ml hydrocortisone, 50 µg/
ml gentamicin, 50 ng/ml amphotericin B, 5 ng/ml recom-
binant human FGF-β and 10 µg/ml heparin. Only cells
from passages four to six were studied in these experi-
ments.
Preparation of the endothelial monolayer has been
described in detail previously [24]. Millicell-HA tissue cul-
ture plate well inserts (12 mm diameter) were obtained
from Millipore (Bedford, MA). The inserts consisted of a
surfactant-free 0.45 µm pore size microporous membrane
filter (manufactured of mixed cellulose) sealed to a cylin-
drical polystyrene holder with an effective membrane sur-
face area of 0.6 cm2. HPAECs suspended in the culture
medium were seeded on the membrane filter at a density
of 4 × 105 cells/filter insert. The inserts were incubated and
placed into 6-well culture plates (Corning Laboratory Sci-
ence, Corning, NY) until permeability measurements
were made.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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Measurement of permeability of endothelial monolayer
As a parameter of endothelial permeability, we measured
the albumin transferred across the HPAEC monolayers
cultured on porous filter [24]. HPAEC were incubated
with TNF-α, LPS and VEGF or combination described
below. The experimental groups were as following;
TNF-α group: incubated with 100 ng/ml of TNF-α for 24
h, LPS group: incubated with 100 ng/ml of LPS for 24 h,
TNF-α+VEGF group: after pre-incubation with 20, 100
and 500 ng/ml VEGF for 48 h, HPAEC were co-incubated
with VEGF and 100 ng/ml TNF-α for 24 h, LPS+VEGF
group: after pre-incubation with 100 and 500 ng/ml VEGF
for 48 h, HPAEC were co-incubated with VEGF and 100
ng/ml LPS for 24 h.
HPAEC monolayers were incubated with culture medium
containing test agent for the experimental protocol at
37°C in a humidified 5% CO2 atmosphere. After aspira-
tion of culture medium, 500 µl of PBS containing 1 mg/
ml bovine serum albumin was added to the upper cham-
ber (the filter insert). The insert was placed in one well of
a 24-well culture plate (Falcon, Becton Dickinson, Frank-
lin Lakes, NJ). After incubation for 20 min, the insert was
removed from the well. The albumin concentration of the
lower chamber was measured with Bio-Rad Protein Assay
kit (Bio-Rad, Hercules, CA).
TUNEL staining of cultured endothelial cells
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) was performed with Apopto-
sis in situ Detection kit (Wako Pure Chemical Industries,
Osaka, Japan). HPAECs were incubated with culture
medium containing test agent for the experimental proto-
col (similar to permeability study). After aspiration of the
test agent and culture medium, HPAEC were fixed with
4% buffered formaldehyde for 10 min and permeabilized
with 0.1% Triton X in sodium citrate for 2 min on ice.
After washing with PBS, the slides were immersed in ter-
minal deoxynucleotidyl transferase (TdT) buffer and incu-
bated in a humid atmosphere at 37°C for 10 min. After
washing with PBS, endogenous peroxidase activity was
q u e n c h e d  w i t h  3 %  H 2O2  for 5 min. The slides were
washed with PBS and incubated with POD-conjugated
antibody in a humid atmosphere at 37°C for 10 min.
After rinsing with PBS, the slides were immersed in DAB
solution for 5 min. The slides were counterstained for 5
min with 1% methyl green. Cells were observed under
microscope and photographed. Apoptotic cell number
was counted in 30 randomly selected fields at ×200 and
expressed as the average number of apoptotic cells per
field.
Active caspase-3 immunoassay
The HPAEC suspended in the culture medium were
seeded on the six-well culture plate and grown to 90%
confluence. The HPAEC were incubated with culture
medium containing test agent for the experimental proto-
col (similar to permeability study). After aspiration of the
test agent and culture medium, extraction buffer contain-
ing protease inhibitors were added, and HPAEC were
scraped. Six-well culture plates were covered and set at
room temperature for 2 h. Calibrator diluent was added
and we obtained 1 × 106 cells/ml extract sample.
To measure active caspase-3, we used human active cas-
pase-3 immunoassay (R&D systems, Minneapolis, MN).
Standards and cell extract samples containing covalently
linked active caspase-3 biotin-ZVKD were pipetted into
the wells, and any caspase-3 present was bound by the
immobilized antibody. Inactive caspase-3 zymogen is not
modified by biotin-ZVKD-fmk inhibitor and therefore
was not detected. Following a wash to remove any
unbound substances, streptavidin conjugated to horserad-
ish peroxidase (HRP) was added to the wells and binds to
the biotin on the inhibitor. Following a wash to remove
any unbound streptavidin-HRP reagents, a substrate solu-
tion was added to the wells. The intensity of the color
measured was in proportion to the amount of active cas-
pase-3 bound in the initial step. The sample values were
then read off the standard curve, followed by cell extract
samples. The optical density was measured at the wave-
length of 450 nm using a microplatereader SJeia II (Sanko
Junyaku, Tokyo, Japan) with correction of wavelength of
570 nm.
Statistical analysis
All values are expressed as mean ± SEM. One-way analysis
of variance (ANOVA) and Scheffe test were used to detect
differences between groups. Statistical significance was
defined as p < 0.05.
Results
Pulmonary endothelial permeability
We measured the lung T/P ratio to assess albumin leakage
into the pulmonary interstitium (Fig. 1a). LPS treatment
significantly increased the T/P ratio compared with the
control animals (p < 0.0001). Anti-VEGF antibody made
no difference in T/P ratio compared with the LPS group,
suggesting that inhibition of VEGF might not influence
LPS-induced pulmonary endothelial damage. Both pre-
and post-treatment with rmVEGF significantly inhibited
this LPS-induced increase in the T/P ratio (p < 0.01, p <
0.05, respectively). It was indicated that exogenous VEGF
may attenuate the albumin leakage from lung microvascu-
lature induced by intratracheal LPS.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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Pulmonary edema formation
We measured the W/D ratio to evaluate extravascular lung
water (Fig. 1b). LPS treatment significantly increased the
W/D ratio compared with the control animals (p < 0.01).
Anti-VEGF antibody made no difference in W/D ratio
compared with the LPS group, suggesting that inhibition
of VEGF might not affect LPS-induced increase in lung
edema formation. Pre-treatment with rmVEGF signifi-
cantly attenuated the LPS-induced increase in the W/D
ratio (p  < 0.05), whereas no difference was observed
between the LPS and the LPS+VEGF (post) groups.
Effect of exogenous VEGF and anti-VEGF antibody on LPS-induced lung injury Figure 1
Effect of exogenous VEGF and anti-VEGF antibody on LPS-induced lung injury. a) T/P ratio 6 h after intratracheal 
LPS instillation. Mice received treatment with either PBS, VEGF or anti-VEGF Ab intravenously. The group with LPS challenge 
revealed increased T/P ratio (*p < 0.0001). The T/P ratio of LPS+anti VEGF Ab group tends to increase compared with that of 
LPS group. In the LPS+VEGF (pre- and post-treatment) groups, T/P ratio was significantly decreased compared with LPS group 
(†p < 0.01, ‡p < 0.05, respectively). n = 6 in each group. b) W/D ratio 6 h after intratracheal LPS instillation. Mice received 
treatment with either PBS, VEGF or anti-VEGF Ab intravenously. The group with LPS challenge revealed increased W/D ratio 
(*p < 0.01). The W/D ratio of LPS+anti VEGF Ab was not significantly different from that of the LPS group. In the LPS+VEGF 
(Pre) group, W/D ratio was significantly decreased compared with the LPS group (†p < 0.05). n = 6 in each group. c) I/T ratio 
6 h after intratracheal LPS instillation. The group with LPS challenge revealed increased I/T ratio (*p < 0.0001) compared with 
the control group. In the anti-VEGF Ab group, I/T ratio was greater than LPS group (†p < 0.05). In the LPS+VEGF (pre) group, 
I/T ratio was significantly decreased compared with LPS group (‡p < 0.0001). n = 6 in each group. d) Emigrated neutrophils 6 h 
after intratracheal LPS instillation. Mice received treatment with either PBS, VEGF or anti-VEGF Ab intravenously. The LPS 
group revealed an increase in emigrated neutrophil (*p < 0.05). Treatment with anti VEGF Ab significantly enhanced neutrophil 
emigration, compared with the LPS group (†p < 0.05). Pre- or post-treatment with VEGF did not affect neutrophil emigration, 
compared with the control and the LPS groups. n = 6 in each group.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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Using a microanalyzer, we determined the I/T ratio of
each field for quantitative evaluation of edema formation
in lung interstitium. An average I/T ratio was calculated
for each animal and shown in Fig. 1c. The I/T ratio in the
LPS group was significantly greater than in the control
group (p < 0.001). The I/T ratio in the LPS+ anti-VEGF
antibody group was significantly greater than in the LPS
group (p < 0.05). The I/T ratio of the LPS+VEGF (pre)
group was significantly decreased compared with the LPS
group (p < 0.0001), whereas the I/T ratio did not differ
between the LPS and LPS+VEGF (post) groups. It was
revealed that the interstitial changes induced by intratra-
cheal LPS are attenuated by exogenous VEGF and accentu-
ated by the blockade of the VEGF cascade.
Neutrophil emigration in alveolar spaces
Emigrated neutrophils were quantified morphologically
in histologic sections (Fig. 1d). LPS treatment significantly
increased the W/D ratio compared with the control ani-
mals (p  < 0.05). Anti-VEGF antibody significantly
enhanced neutrophil emigration compared with the LPS
group (p < 0.05). Emigrated neutrophils in the LPS+VEGF
(pre) and the LPS+VEGF (post) groups were not signifi-
cantly different from those in the LPS group.
TUNEL staining of lung specimens
We performed TUNEL staining on lung sections to deter-
mine the effect of VEGF on LPS-induced apoptosis of lung
cells (Fig. 2a). We observed characteristic chromatin con-
densation in the nuclei of TUNEL-positive epithelial and
endothelial cells in the LPS group. There were fewer
TUNEL-positive cells in the LPS+VEGF group than in the
LPS group, suggesting that exogenous VEGF attenuates
LPS-induced apoptosis of epithelial and endothelial cells.
Immunohistochemistry of lung specimens
We performed immunohistochemical staining of lung tis-
sue specimens with the anti-human caspase-3 rabbit pol-
yclonal antibody (Fig. 2b), anti-human Bax rabbit
polyclonal antibody (Fig. 2c), anti-human AIF rabbit pol-
yclonal antibody (Fig. 2d), and anti-mouse anti-cyto-
chrome C monoclonal antibody (Fig. 2e). In the LPS
group, caspase-3, Bax, AIF, and cytochrome C immunos-
taining were present in epithelial and endothelial cells,
but not in macrophages and neutrophils. VEGF treatment
decreased the number of cells positive for these markers,
indicating that exogenous VEGF inhibited the apoptosis
cascade induced by intratracheal LPS in epithelial and
endothelial cells.
Permeability of endothelial monolayer
To determine the protective effect of VEGF on the
endothelial cells, we measured the albumin influx into
the lower chamber through the endothelial monolayer. If
the tightness of the monolayer is kept, little albumin trav-
els through. Compared with the controls, treatment with
TNF-α at concentrations of (100 and 1,000 ng/ml) for 24
h caused a dose-dependent increase in the albumin con-
centration in the lower chamber (data not shown). TNF-α
at 1,000 ng/ml induced a similar increase as 100 ng/ml,
suggesting that 100 ng/ml of TNF-α is sufficient to evalu-
ate the effects of VEGF on the endothelial injury induced
by TNF-α. On the other hand, VEGF alone (20, 100 and
500 ng/ml) did not change albumin transfer, although the
expression of two types of VEGF receptor, VEGF-R1 and
VEGF-R2, on HPAEC was confirmed (data not shown).
VEGF significantly reduced TNF-α-induced albumin
transfer to the lower chamber (p < 0.001; Fig. 3a). There
was no significant difference in the albumin transfer
between the control and the TNF-α + VEGF (each concen-
tration) groups. VEGF (all concentrations) also signifi-
cantly inhibited LPS-induced albumin transfer (p < 0.002,
Fig. 3b). There was no significant difference in the albu-
min transfer between the control and the LPS + VEGF (500
ng/ml) groups, whereas the albumin transfer was signifi-
cantly greater in the LPS + VEGF (100 ng/ml) group than
in the control group (p < 0.001).
TUNEL staining of HPAEC
The TUNEL method was used to detect apoptotic cells.
TNF-α treatment increased the number of apoptotic cells,
which was significantly reduced by VEGF at 500 ng/ml (p
< 0.001), but not at 100 ng/ml (Fig. 4a). LPS treatment
also increased the number of apoptotic cells, and signifi-
cantly fewer apoptotic cells were observed in the
LPS+VEGF groups than in the LPS group (p < 0.001, Fig.
4b). There was no significant difference between control
and LPS+VEGF groups. Representative photomicrographs
of HPAEC after TUNEL staining are shown in Fig. 4c.
Active caspase-3 immunoassay of HPAEC
Active caspase-3 was detected with a human active cas-
pase-3 immunoassay. Stimulation with TNF-α (10 ng/ml)
for 4 h significantly increased the level of active caspase-3
compared with control (p < 0.0001), but, at 24 h, there
was no significant difference between control and TNF-α-
stimulated cells. Stimulation with 100 ng/ml TNF-α
increased the levels of active caspase-3 compared with
control at 4 h and 24 h (p < 0.0001 and p < 0.01, respec-
tively, Fig. 5a). LPS (10 ng/ml) did not significantly
increase the levels of active caspase-3. There was no signif-
icant difference between control and 10 ng/ml LPS at 4, 8
and 24 h, whereas 100 ng/ml LPS significantly increased
active caspase-3 at 8 h and 24 h (p < 0.0001, Fig. 5b).
VEGF significantly reduced the levels of TNF-α-induced
active caspase-3 (p < 0.001, Fig. 5c). There was no signifi-
cant difference in active caspase-3 between the control
and the TNF-α+VEGF groups. VEGF also significantlyRespiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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Representative appearances of lung tissue specimen after TUNEL and immunohistochemical staining Figure 2
Representative appearances of lung tissue specimen after TUNEL and immunohistochemical staining. a) In the 
LPS group, characteristic chromatin condensation in the nuclei of TUNEL-positive epithelial and endothelial cells were 
observed, which were decreased in the LPS+VEGF group. b-e) Caspase-3 (b), Bax (c), AIF (d) and cytochrome C (e) immu-
nostaining were present in epithelial and endothelial cells, but not in macrophages and neutrophils. In the LPS+VEGF group, 
TUNEL, caspase-3, Bax, AIF and cytochrome C positive cells were decreased compared with the LPS group. Scale bar = 50 
µm.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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Effect of VEGF on endothelial damage induced by TNF-α and LPS Figure 3
Effect of VEGF on endothelial damage induced by TNF-α and LPS. a) VEGF significantly reduced albumin transfer to 
the lower chamber that was induced by TNF-α stimulation for 24 h. *p < 0.001 vs control; †p < 0.001 vs TNF-α. b) VEGF sig-
nificantly inhibited LPS-induced albumin transfer to the lower chamber. *p < 0.001 vs control; †p < 0.002 vs LPS; ‡p < 0.001 vs 
LPS. n = 12 in each group.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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decreased the levels of LPS-induced active caspase-3 (p <
0.001, Fig. 5d). The levels of active caspase-3 in the con-
trol and the LPS+VEGF groups were similar. It was sug-
gested that VEGF might suppress the activation of caspase-
3 induced by TNF-α and LPS.
Discussion
In the present study, we have observed that exogenous
VEGF significantly decreased LPS-induced extravascular
albumin leakage and edema formation. In contrast, VEGF
blockade by monoclonal antibody enhanced tissue
edema and neutrophil emigration on lung pathology. Pre-
treatment with VEGF significantly decreased the number
of cells labeled with TUNEL staining and immunostaining
of the pro-apoptotic proteins caspase-3, Bax, AIF, and
cytochrome C. VEGF attenuated the increases in permea-
bility of the HPAEC monolayer and the apoptosis of
HPAECs induced by TNF-α and LPS. In addition, VEGF
significantly reduced the levels of TNF-α- and LPS-
induced active caspase-3 in HPAEC lysates. These results
suggest that VEGF suppresses the apoptosis induced by
inflammatory stimuli and plays a protective role during
acute lung injury.
Apoptosis is an essential physiological process for the
selective elimination of cells, which can be triggered by
surface receptors, which interact with soluble proteins or
membrane-bound proteins. Dysregulation of apoptosis
pathways could contribute to the endothelial and epithe-
lial injury that is characteristic of ALI/ARDS in humans
[25]. In this study, pre-incubation with VEGF significantly
attenuated the increase in the permeability of the
endothelial monolayer, suggesting that VEGF protects
against endothelial damage induced by TNF-α and LPS.
To investigate the mechanism underlying this attenuation
of endothelial damage, the effects of VEGF on apoptosis
and activation of caspase-3, one of the effector caspases
that initiate and execute cell death, were evaluated using
Effect of VEGF on endothelial cell apoptosis assessed by TUNEL method Figure 4
Effect of VEGF on endothelial cell apoptosis assessed by TUNEL method. a) The number of TUNEL positive cells 
after TNF-α stimulation for 24 h. *p < 0.001 vs control; †p < 0.001 vs TNF-α. b) The number of TUNEL positive cells after 
LPS stimulation for 24 h. *p < 0.0001 vs control; †p < 0.001 vs LPS. n = 4 in each group. c) TUNEL method in HPAEC. Cells 
were unstimulated or stimulated by TNF-α, LPS, with or without the pretreatment of VEGF. Scale bar = 50 µm.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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HPAEC. Pre-incubation with VEGF significantly reduced
the number of apoptotic cells and levels of active caspase-
3, which is consistent with the observations of a previous
study [19]. It was also reported that recombinant VEGF
inhibited apoptosis of liver and renal cells and improved
hepatic and renal dysfunctions during experimental pan-
creatitis [26]. They concluded that VEGF might function
as a protective factor via the anti-apoptotic effect against
the organ injury [26]. In this study, since TUNEL staining
indicated attenuation of apoptosis of lung cells, we
immunohistochemically evaluated the expression of four
pro-apoptotic proteins, caspase-3, Bax, AIF and cyto-
chrome C, in the lung. Bax is a member of the pro-apop-
totic Bcl-2 family, which modulates death signaling and
leads to the release of pro-apoptotic molecules from the
mitochondrial intermembranous space, such as cyto-
chrome C and AIF. Cytochrome C induces cell death by
activation of caspase-9 and -3, whereas AIF leads to detri-
mental DNA damage by a caspase-independent pathway.
We found that the expression of all of the apoptosis-asso-
ciated molecules examined was attenuated by exogenous
VEGF. Munshi and colleagues showed that VEGF inhib-
ited the induction of Bax and activation of caspase-3 in
LPS-induced endothelial apoptosis, a finding that is com-
parable to our result [27]. To the best of our knowledge,
there has been no report on the effects of VEGF on the
Effect of VEGF on endothelial cell apoptosis assessed by active caspase-3 in cell lysates Figure 5
Effect of VEGF on endothelial cell apoptosis assessed by active caspase-3 in cell lysates. a) Stimulation with 100 ng/
ml TNF-α stimulation for 4 and 24 h increased the levels of active caspase-3. *p < 0.0001 vs control; †p < 0.01 vs control. b) 
LPS stimulation for 4, 8 and 24 h. Higher concentration (100 ng/ml) of LPS significantly increased active caspase-3 at 8 h and 24 
h. *p < 0.0001 vs control. c) VEGF significantly reduced the levels of TNF-α-induced active caspase-3. *p < 0.0001 vs control; 
†p < 0.0001 vs TNF-α. d) VEGF significantly decreased the levels of LPS-induced active caspase-3. *p < 0.0001 vs control; †p < 
0.0001 vs LPS. n = 4 in each group.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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mitochondrial proteins AIF and cytochrome C. Pretreat-
ment with VEGF inhibits the release of AIF and cyto-
chrome C from the mitochondrial intermembranous
space, although it remains to be determined which mole-
cule of the apoptotic cascade VEGF affects. In addition to
the inhibition of pro-apoptotic proteins, it was also
reported that VEGF induces up-regulation of the anti-
apoptotic proteins Bcl-2 and A1 in endothelial cells,
which may be another mechanism for its inhibition of
apoptosis [19,20]. Although other mechanisms could be
involved, we concluded that VEGF-induced inhibition of
apoptosis of endothelial cells might reduce albumin leak-
age through the pulmonary microvascular endothelium,
leading to attenuation of lung injury.
In this study, we showed that VEGF attenuated the
increases in the permeability of HPAEC monolayer and
the apoptosis of HPAECs induced by TNF-α and LPS. It
was also revealed that, during recovery from hyperoxic
lung injury, when endothelial cells proliferate, VEGF
mRNA becomes very abundant in alveolar type II cells
[28]. In addition, the VEGF synthesized by the lung epi-
thelial cells is known to contribute to the endothelial
repair and angiogenesis processes following lung injury
[29]. VEGF contributes to restoration of the cultured epi-
thelial cell proliferation in an acid exposure model of
injury [30]. We observed that the number of TUNEL-pos-
itive cells was decreased in the LPS+VEGF group com-
pared with the LPS group. It is possible that VEGF may be
associated with the protection and repair of the pulmo-
nary endothelium and epithelium in the later phase of
ALI/ARDS. Since our study limited its evaluation of the
effects of VEGF to the acute phase of LPS-induced lung
injury, the effects of exogenous VEGF or the anti-VEGF
antibody at the later time points remain to be clarified.
In the lungs, VEGF mRNA is expressed primarily by alveo-
lar epithelial cells and activated alveolar macrophages,
which suggests that alveolar epithelial cells and macro-
phages may be potential sources of VEGF in the lungs
[8,10,31]. VEGF protein is secreted by alveolar cell-like
cell lines in response to a number of pro-inflammatory
stimuli potentially involved in ALI/ARDS, such as LPS and
neutrophil elastase [32]. However, a number of clinical
investigations have shown that, during ALI/ARDS, the
VEGF level in the lung was decreased, while the plasma
concentration of VEGF is the same or increased [14-
16,18,33]. The elevated plasma VEGF level could be
derived from the molecule that constitutively exists in the
alveolar space and leaks into the bloodstream [10]. In this
study, we administered rmVEGF and anti-VEGF antibody
intravenously. It is unclear whether rmVEGF and anti-
VEGF antibody reached the alveolar space. However, it is
not unreasonable to assume that they at least acted on the
pulmonary vascular endothelial cells. Considering the
impaired barrier function of vascular endothelium in the
injured lung, we think it is possible that those agents
administered intravenously might produce an effect on
alveolar epithelial cells.
In this study, blockade of the VEGF cascade by anti-VEGF
antibody significantly enhanced lung edema formation,
as documented by the increased I/T ratio, after intratra-
cheal LPS administration, although extravascular albumin
leakage was not significantly changed. Usually, patholog-
ical changes occur after endothelial permeability is
increased. We speculated that the difference in I/T ratio
reached significance because the increase in the endothe-
lial permeability was slight but sustained.
VEGF was originally discovered as a vascular permeability
factor. Several in vitro studies revealed that VEGF treat-
ment increases the endothelial permeability [4,34]. Kaner
and coworkers delivered VEGF165 complementary DNA to
the respiratory epithelium by an E1- adenovirus vector
and observed that overexpression of the VEGF gene
induced pulmonary edema [13]. These previous observa-
tions indicate that VEGF increases endothelial permeabil-
ity leading to pulmonary edema, whereas our data suggest
that VEGF has a protective role during lung injury.
Although it is difficult to compare the data from separate
studies, we speculate that the function of VEGF may be
different between normal lung and during severe lung
inflammation. In in vitro and ex vivo studies using a variety
of VEGF concentrations, the different species and meth-
ods used may have contributed to the apparent differ-
ences in the previously reported findings [35]. In a recent
report, Mirzapoiazova and coworkers showed that the
barrier properties of cultured HPAEC were improved by
10 ng/ml VEGF but decreased by 100 ng/ml VEGF [36].
They concluded that VEGF might cause diverse effects on
pulmonary endothelial permeability depending on its
concentration [36]. Another possible mechanism may be
that the VEGF signaling pathway might be switched to an
alternative pathway by the inflammatory stimuli or medi-
ators that are associated with the pathogenesis of ALI/
ARDS.
Conclusion
In summary, the results of the present study suggest that
VEGF may suppress the apoptosis cascade and attenuate
the increased endothelial permeability and edema forma-
tion following intratracheal administration of inflamma-
tory stimuli. We conclude that VEGF functions as a
protective factor for the injured lung during the develop-
ment of ALI/ARDS. Further investigation will be needed to
determine whether VEGF or related molecules could be a
therapeutic modality for this refractory disease.Respiratory Research 2007, 8:60 http://respiratory-research.com/content/8/1/60
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